| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 51,298 | 48,502 | 32,704 | 33,251 |
| Cost of sales | 5,499 | 5,543 | 3,648 | 3,828 |
| Research and development | 46,027 | 42,308 | 36,973 | 37,931 |
| Selling, general, and administrative | 52,425 | 45,947 | 39,087 | 35,377 |
| Total costs and expenses | 103,951 | 93,798 | 79,708 | 77,136 |
| Loss from operations | -52,653 | -45,296 | -47,004 | -43,885 |
| Other income (expense), net | 274 | 1,576 | -644 | 1,088 |
| Interest expense | 4,742 | 5,817 | 5,409 | 5,242 |
| Interest income | 4,328 | 3,242 | 3,639 | 4,054 |
| Total other (expense), net | -140 | -999 | -2,414 | -100 |
| Loss before income taxes | -52,793 | -46,295 | -49,418 | -43,985 |
| Provision for income taxes | 111 | 337 | 80 | -344 |
| Net loss | -52,904 | -46,632 | -49,498 | -43,641 |
| Accrued dividends on convertible preferred stock | 1,375 | 1,349 | 1,322 | 1,329 |
| Net loss attributable to common stockholders | -54,279 | -47,981 | -50,820 | -44,970 |
| Earnings per share, basic | -0.82 | -0.75 | -0.81 | -0.73 |
| Earnings per share, diluted | -0.82 | -0.75 | -0.81 | -0.73 |
| Weighted average number of shares outstanding, basic | 66,261,055 | 63,684,359 | 63,059,165 | 61,219,918 |
| Weighted average number of shares outstanding, diluted | 66,261,055 | 63,684,359 | 63,059,165 | 61,219,918 |
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)